Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 8/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | CDC25C | P30307 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12137350 | 0.86 | NQO1 (0.41) | HSD17B3ESR1ESR2CDC25ACDC25C | |
| SCHEMBL12137348 | 0.81 | ESR1 (0.42) | HSD17B3ESR1ESR2PKLRNPSR1 | |
| SCHEMBL1357283 | 0.78 | ESR1 (0.48) | HSD17B3ESR1ESR2MIFCA9 | |
| Asphodelin A SCHEMBL29386434 | 0.71 | NOX4 (0.67) | HSD17B3ESR1ESR2PKLRNPSR1 | |
| SCHEMBL5109410 | 0.69 | ESR1 (0.81) | HSD17B3ESR1ESR2PKLRNOX4 | |
| SCHEMBL27886627 | 0.67 | ALDH1A1 (0.62) | HSD17B3CA9LMNAKDM4EMEN1 | |
| SCHEMBL27981344 | 0.66 | HSD17B3 (0.69) | HSD17B3ESR1ESR2CA9PKLR | |
| SCHEMBL14277816 | 0.66 | ESR1 (0.60) | HSD17B3ESR1ESR2PKLRNPSR1 | |
| SCHEMBL5111890 | 0.65 | ESR1 (0.58) | HSD17B3ESR1ESR2PKLRNPSR1 | |
| SCHEMBL13314111 | 0.65 | USP2 (0.56) | HSD17B3ESR1ESR2CA9CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | claimed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | claimed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | claimed |
| CN-101142203-A | Novel coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-12 | — | — | CN | claimed |
| EP-1846386-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | claimed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | claimed |
| WO-2006078833-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | WO | claimed |
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-8067619-B2 | Coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-11-29 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JAIN NARESHKUMAR F | 2010-03-18 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662975-B2 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-16 | — | — | US | disclosed |
| CN-101142203-A | Novel coumarin derivatives as ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-12 | — | — | CN | disclosed |
| EP-1846386-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006078833-A2 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069474-A1 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS | KCNJ2, KCNN3, KCNN2 | HSD17B3 3296/4885ESR1 3463/4885ESR2 2401/4885 |
| US-20070037877-A1 | trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity | KCNN2, KCNH3, KCNN1 | HSD17B3 517/4885ESR1 226/4885ESR2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.